相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Interlaboratory variability of Ki67 staining in breast cancer
Cornelia M. Focke et al.
EUROPEAN JOURNAL OF CANCER (2017)
Biomarkers in phase I-II chemoprevention trials: lessons from the NCI experience
Eva Szabo
ECANCERMEDICALSCIENCE (2015)
Randomized Phase II Trials Time for a New Era in Clinical Trial Design
Sumithra J. Mandrekar et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Optimising the design of phase II oncology trials: The importance of randomisation
Mark J. Ratain et al.
EUROPEAN JOURNAL OF CANCER (2009)
Randomized phase II designs in cancer clinical trials: Current status and future directions
JJ Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial
M Mengel et al.
JOURNAL OF PATHOLOGY (2002)
Why phase II trials in cervical chemoprevention are negative: what have we learned?
M Follen et al.
CANCER CAUSES & CONTROL (2002)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
分享论文
